Last Updated : May 21, 2024
Details
Generic Name:
ibrutinib
Project Status:
Not filed
Therapeutic Area:
Leukemia
Manufacturer:
Janssen Canada Inc.
Brand Name:
Imbruvica
Project Line:
Reimbursement Review
Project Number:
NS0004-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
In combination with obinutuzumab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL).
Recommendation Type:
Unable to recommend reimbursement
CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.
Last Updated : May 21, 2024